2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade

The article sees recovery potential in Netflix and Intuitive Surgical despite recent challenges. Netflix viewing hours rose only 2% year over year in the first half, but its large subscriber ecosystem and potential moves into sports and streaming aggregation could create monetization opportunities. Intuitive Surgical has nearly 12,000 da Vinci systems installed, while fewer than 8% of relevant soft-tissue procedures are performed robotically; its shares are down about 30% this year, and the article argues that market growth and newer systems could support a longer-term rebound.

Analysis

Engagement, not audience scale, is Netflix’s near-term underwriting variable. Sports can create appointment viewing and improve ad inventory, but rights bids also risk converting an engagement problem into a content-cost problem. A streaming hub could increase retention while weakening Netflix’s control of the customer relationship; neither strategy is proven by the reported opportunity set. The key read-through over the next 1–3 months is whether viewing, churn and ad monetization improve without a corresponding deterioration in content economics. Over 6–18 months, sustained engagement gains could support better monetization; failure to show them would leave the recovery case dependent on an unverified option value.

Intuitive Surgical’s moat is operational as well as installed-base scale: training and workflow familiarity can slow adoption of rival systems. But underpenetration is not guaranteed demand for any one vendor. Competitors Medtronic (MDT) and Johnson & Johnson (JNJ) can pressure placements and pricing, while a costly new-system transition may weigh on margins before utilization and recurring procedure-related revenue catch up. The medium-term test is procedure growth and system utilization alongside margin recovery—not launches alone. Aging demographics are a gradual tailwind, not a near-term catalyst. Both recovery narratives may already be reflected in expectations; the article provides no valuation or forward-estimate data to establish that either is mispriced.

Key Decisions for Investors

• Netflix: Keep on a catalyst watch rather than chase a recovery thesis. Consider initiating only after evidence of improving viewing hours, churn or ad monetization without accelerating content-cost pressure. Reassess if engagement remains weak or sports-rights spending rises without measurable retention gains.
• Intuitive Surgical: Prefer a staged entry after confirming procedure growth, utilization of newer systems and stabilization in margins. Track rival system placements and adoption; faster competitor uptake or persistent margin deterioration would falsify the moat-to-earnings conversion thesis.
• Avoid treating MDT or JNJ as clean shorts on this article alone: their robotic-surgery launches create competitive optionality, but no adoption, revenue or return data are supplied to size the impact. Monitor placement wins and hospital purchasing decisions before taking a relative-value position.
• Before either position, verify current valuation, consensus estimates and the next reported operating metrics. The article’s long-term narratives do not establish near-term upside or downside, and there may be no trade until operating evidence arrives.